PRT062607 (P505-15) HCl

Catalog No.S8032 Batch:S803201

Print

Technical Data

Formula

C19H23N9O.HCl

Molecular Weight 429.91 CAS No. 1370261-97-4
Solubility (25°C)* In vitro DMSO 86 mg/mL (200.04 mM)
Water 86 mg/mL (200.04 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Targets
Syk [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
MLK1 [1]
(Cell-free assay)
PYK2 [1]
(Cell-free assay)
YES [1]
(Cell-free assay)
View More
1 nM 81 nM 88 nM 108 nM 123 nM
In vitro PRT062607(P505-15) anti-SYK activity is at least 80-fold greater than its affinity for other kinases. at least 80-fold greater than its affinity for other kinases. PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). [1] PRT062607 inhibits BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT062607 furthermore inhibits Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. [2]
In vivo The pharmacokinetic/pharmacodynamic relationship predicted that 70% Syk suppression is maintained in mice over a 24h period after 30 mg/kg dosing. At 15 mg/kg, Syk inhibition ranges from 7.5% (Cmin) to 78.4% (Cmax) with an average inhibition of 67% over 24 h. Oral administration of PRT062607 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis. Statistically significant efficacy is observed at concentrations that specifically suppressed Syk activity by 67%.[1]

Protocol (from reference)

Kinase Assay:

[1]

  • fluorescence resonance energy transfer (FRET) assay

    The extent of substrate phosphorylation by Syk is measured in the presence of various PRT062607 concentrations. Syk activity is determined by a fluorescent antibody specific for phosphorylated tyrosine by using the increase of FRET. Twelve concentrations are tested for dose response. Specificity and potency of kinase inhibition is determined by evaluation of PRT062607 in the Millipore KinaseProfiler panel of 270 independent purified kinase assays. For profiling, PRT062607 is tested in duplicate at two concentrations at a fixed concentration of ATP. Subsequently, IC50 determinations using the radioactive assays are carried out at an ATP concentration optimized for each individual kinase. All radioactive ATP incorporationenzyme assays are performed at Millipore.

Cell Assay:

[1]

  • Cell lines

    Syk-dependent BaF3 cell

  • Concentrations

    ~6 μM

  • Incubation Time

    3 days

  • Method

    CellTiter Glo

Animal Study:

[1]

  • Animal Models

    Mouse Collagen Antibody-Induced Arthritis Model

  • Dosages

    5, 15, 30 mg/kg, b.i.d.

  • Administration

    Oral

Customer Product Validation

Data from [Data independently produced by Exp Dermatol, 2014, 23(12), 884-9]

Data from [Data independently produced by , , Nature, 2015, 521(7552): 357-61]

Data from [Data independently produced by , , Nature, 2015, 521(7552): 357-61]

Data from [Data independently produced by , , Haematologica, 2016, 101(2):e59-62.]

Selleck's PRT062607 (P505-15) HCl has been cited by 54 publications

Identification and structural characterization of small molecule inhibitors of PINK1 [ Sci Rep, 2024, 14(1):7739] PubMed: 38565869
TLR7/8 stress response drives histiocytosis in SLC29A3 disorders [ J Exp Med, 2023, 220(9)e20230054] PubMed: 37462944
TLR7/8 stress response drives histiocytosis in SLC29A3 disorders [ J Exp Med, 2023, 220(9)e20230054] PubMed: 37462944
Neuronal C-Reactive Protein/FcγRI Positive Feedback Proinflammatory Signaling Contributes to Nerve Injury Induced Neuropathic Pain [ Adv Sci (Weinh), 2023, 10(10):e2205397] PubMed: 36727833
Protease-activated receptors and glycoprotein VI cooperatively drive the platelet component in thromboelastography [ J Thromb Haemost, 2023, 21(8):2236-2247] PubMed: 37068592
YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1 [ Biomolecules, 2023, 13(6)949] PubMed: 37371529
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia [ Cancer Cell, 2022, S1535-6108(22)00312-9] PubMed: 35868306
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia [ Nat Commun, 2022, 13(1):6226] PubMed: 36266272
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia [ Nat Commun, 2022, 13(1):6226] PubMed: 36266272
Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL [ Mol Syst Biol, 2022, 18(8):e10855] PubMed: 35959629

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.